GUANGZHOU, China, May 15, 2026 /PRNewswire/ — Pomdoctor Limited (“Pomdoctor” or the “Company”) (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its financial results for the fiscal year ended December 31, 2025.
Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: “Fiscal year 2025 marked a year of solid revenue expansion and continued execution of our growth strategy. Both our net revenues and gross profit recorded solid year-over-year increases, by 16.7% and 9.6% respectively, primarily driven by the strong growth of our Internet hospital business, particularly online pharmacy sales as we deepened collaboration with pharmaceutical manufacturers. At the same time, we achieved a steady gross margin over 13%, reflecting our capability in maintaining profit while continuing expansion of our business scale, executing sales promotions and obtaining new customers.
“During the year, we also increased our investments in research and development (“R&D”) by 328.5% to support our long-term strategic priorities. Our R&D efforts are focused on enhancing our technology-driven healthcare capabilities and strengthening our platform infrastructure, which we believe will enable us to deliver more efficient and accessible healthcare services while supporting sustainable growth over time.
“Despite the net loss for the year, which was primarily attributable to significant non-recurring expenses associated with our initial public offering, including professional service fees and investor relations initiatives, we view these costs as necessary and strategic investments. These investments enabled our transition to a publicly listed company, strengthened our corporate governance, enhanced our operational and financial capabilities, and unlocked broader growth opportunities for the future. Following our successful listing, we are now better positioned to access capital market resources to support business expansion and execute our long-term growth strategy more efficiently on a larger scale.
“Looking ahead, we remain confident in the long-term growth potential of China’s digital healthcare market. We will continue to deepen strategic partnerships with pharmaceutical companies to further drive Internet hospital growth, accelerate the integration of our platform with online medical insurance systems across major cities, and advance our strategic upgrade centered on ‘artificial intelligence (AI) + medical-grade smart wearables + full-cycle chronic disease management.’ We believe these initiatives will strengthen our ecosystem and position us for scalable growth and long-term value creation.”
Fiscal Year 2025 Financial Summary
- Net revenues were RMB399.9 million (US$57.2 million) in fiscal year 2025, an increase of 16.7% from RMB342.6 million in fiscal year 2024.
- Gross profit was RMB52.3 million (US$7.5 million) in fiscal year 2025, an increase of 9.6% from RMB47.7 million in fiscal year 2024.
- Gross margin was 13.1% in fiscal year 2025, compared to 13.9% in fiscal year 2024.
- Net loss was RMB130.9 million (US$18.7 million) in fiscal year 2025, compared to RMB37.4 million in fiscal year 2024.
- Basic and diluted loss per share were RMB21.96 (US$3.14) in fiscal year 2025, compared to RMB22.72 in fiscal year 2024.
Fiscal Year 2025 Financial Results
Net Revenues
Net revenues were RMB399.9 million (US$57.2 million) in fiscal year 2025, an increase of 16.7% from RMB342.6 million in fiscal year 2024.
- Net revenues from Internet hospital were RMB150.7 million (US$21.6 million) in fiscal year 2025, an increase of 69.3% from RMB89.0 million in fiscal year 2024. The increase was primarily due to the increase in revenues generated from online pharmacy sales. In fiscal year 2025, the Company deepened cooperation with pharmacy manufacturers to sell their products through its Internet hospital platform, which led to that revenue from the Company’s online pharmacy sales increased from RMB87.8 million in fiscal year 2024 to RMB149.2 million (US$21.3 million) in fiscal year 2025. Revenue from online consultation service slightly increased from RMB1.2 million in fiscal year 2024 to RMB1.5 million (US$0.2 million) in fiscal year 2025.
- Net revenues from pharmaceutical supply chain were RMB249.2 million (US$35.6 million) in fiscal year 2025, a decrease of 1.7% from RMB253.5 million in fiscal year 2024, primarily driven by the decrease in the Company’s pharmacy wholesale business from RMB246.9 million in fiscal year 2024 to RMB243.2 million (US$34.8 million) in fiscal year 2025, as a result of the Company’s stable pharmaceutical supply chain business and reduction cooperation with the customers whose credit terms were relatively longer than others. Because of high competition of retail pharmacy store, two of the Company’s retail sales stores were closed in fiscal year 2025, which led to that the revenues from pharmacy retail sales also decreased from RMB6.6 million in fiscal year 2024 to RMB6.0 million (US$0.9 million) in fiscal year 2025.
Cost of Revenues
Cost of revenue was RMB347.6 million (US$49.7 million) in fiscal year 2025, an increase of 17.9% from RMB294.9 million in fiscal year 2024. The increase was primarily due to the increase in cost of revenues in online pharmacy sales from RMB51.0 million in fiscal year 2024 to RMB101.4 million (US$14.5 million) in fiscal year 2025, which was in line with the increase in the Company’s net revenues from Internet hospital. The cost of revenues in pharmaceutical supply chain increased from RMB243.9 million in fiscal year 2024 to RMB246.2 million (US$35.2 million) in fiscal year 2025.
Gross Profit and Gross Margin
Gross profit was RMB52.3 million (US$7.5 million) in fiscal year 2025, an increase of 9.6% from RMB47.7 million in fiscal year 2024.
Gross margin was 13.1% in fiscal year 2025, slightly decreased from 13.9% in fiscal year 2024.
- Gross profit margin of Internet hospital was 32.7% in fiscal year 2025, decreased from 42.7% in fiscal year 2024. The decrease mainly attributable to the increase in the online pharmacy sales of products with lower gross profit margin.
- Gross profit margin of pharmaceutical supply chain was 1.2% in fiscal year 2025, decreased from 3.8% in fiscal year 2024. The decrease was primarily because the gross profit margin of the Company’s pharmacy wholesale customers newly obtained in fiscal year 2025 was lower than that of customers in fiscal year 2024.
Operating Expenses
Total operating expenses were RMB170.9 million (US$24.4 million) in fiscal year 2025, compared to RMB73.5 million in fiscal year 2024.
- Sales and marketing expenses were RMB96.2 million (US$13.8 million) in fiscal year 2025, increased by 70.7% from RMB56.4 million in fiscal year 2024. The increase primarily due to the increase in professional service fees paid to outsourced consultants for promoting the Company’s brand and internet medical platform of approximately RMB36.5 million (US$5.2 million) and service fees to doctors and staff costs which is in line of the increase in the revenues from Internet hospital business.
- General and administrative expenses were RMB59.7 million (US$8.5 million) in fiscal year 2025, increased by 402.9% from RMB11.9 million in fiscal year 2024. The increase primarily due to (i) increase in professional service fee paid to outsourced consultants for consultancy for investor relationship management of approximately RMB38.0 million (US$5.4 million) incurred in fiscal year 2025; and (ii) the increase in consulting service fee and office fees of RMB6.5 million (US$0.9 million) paid during the process of initial public offering, primarily offset by the decrease in expected credit loss recognized resulting from the efforts for collection of accounts receivable.
- Research and development expenses were RMB12.9 million (US$1.8 million) in fiscal year 2025, increased by 328.5% from RMB3.0 million in fiscal year 2024. The increase primarily due to a new research and development project, especially in AI and healthcare-related AI applications, launched in fiscal year 2025 and related consulting service fee paid.
- Impairment loss on property and equipment and operating lease right-of-use assets with definite lives of RMB2.2 million and RMB2.1 million (US$0.3 million) in fiscal year 2024 and 2025, respectively.
Net Loss
Net loss was RMB130.9 million (US$18.7 million) in fiscal year 2025, compared to RMB37.4 million in fiscal year 2024.
Basic and Diluted Loss per Share
Basic and diluted loss per share were RMB21.96 (US$3.14) in fiscal year 2025, compared to RMB22.72 in fiscal year 2024.
Financial Condition
As of December 31, 2025, the Company had cash and cash equivalents of RMB9.6 million (US$1.4 million), compared to RMB7.7 million as of December 31, 2024.
Net cash used in operating activities in fiscal year 2025 was RMB148.5 million (US$21.2 million), compared to RMB16.1 million in fiscal year 2024.
Net cash used in investing activities in fiscal year 2025 was RMB1.6 million (US$0.2 million), compared to RMB0.03 million in fiscal year 2024.
Net cash provided by financing activities in fiscal year 2025 was RMB153.9 million ($22.0 million), compared to RMB17.0 million in fiscal year 2024.
Exchange Rate Information
This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB6.9931 to US$1.00, the rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board on December 31, 2025.
Recent Development
On October 9, 2025, the Company completed its initial public offering (the “Offering”) of 5,000,004 American Depositary Shares (“ADSs”) at a public offering price of US$4.00 per ADS. On October 10, 2025, the underwriter of the Offering fully exercised its over-allotment option to purchase an additional 750,000 American Depositary Shares of the Company at the public offering price of US$4.00 per ADS. The gross proceeds were US$23,000,016 from the Offering, before deducting underwriting discounts and commissions, and other expenses. The Company’s ADSs began trading on the Nasdaq Global Market on October 8, 2025 under the ticker symbol “POM.”
About POMDOCTOR LIMITED
POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China’s Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company’s operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company’s mission is to provide effective prevention and treatment solutions to alleviate patients’ sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company’s website: http://ir.7shiliu.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: [email protected]
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]
POMDOCTOR LIMITED
CONSOLIDATED BALANCE SHEETS
|
December 31, 2024 |
December 31, 2025 |
December 31, 2025 |
||||||||||||||||||||||||
|
RMB |
RMB |
US$ |
||||||||||||||||||||||||
|
Assets |
||||||||||||||||||||||||||
|
Current assets: |
||||||||||||||||||||||||||
|
Cash and cash equivalents (including amounts of the consolidated VIEs of RMB7,596,708 and RMB8,445,208 (US$1,207,649) as of December 31, 2024 and 2025, respectively) |
7,651,695 |
9,580,367 |
1,369,974 |
|||||||||||||||||||||||
|
Accounts receivable, net (including amounts of the consolidated VIEs of RMB8,374,608 and RMB18,440,482 (US$2,636,954) as of December 31, 2024 and 2025, respectively) |
8,374,608 |
18,440,482 |
2,636,954 |
|||||||||||||||||||||||
|
Accounts receivable – a related party (including amounts of the consolidated VIEs of RMB424,259 and RMB831,436 (US$118,894) as of December 31, 2024 and 2025, respectively) |
424,259 |
831,436 |
118,894 |
|||||||||||||||||||||||
|
Amount due from related parties (including amounts of the consolidated VIEs of RMB6,070,945 and RMB3,637,039 (US$520,090) as of December 31, 2024 and 2025, respectively) |
5,632,987 |
3,637,039 |
520,090 |
|||||||||||||||||||||||
|
Inventories (including amounts of the consolidated VIEs of RMB9,165,973 and RMB8,280,145 (US$1,184,045) as of December 31, 2024 and 2025, respectively) |
9,165,973 |
8,280,145 |
1,184,045 |
|||||||||||||||||||||||
|
Other receivables, net (including amounts of the consolidated VIEs of RMB5,318,724 and RMB5,824,886 (US$832,948) as of December 31, 2024 and 2025, respectively) |
5,318,724 |
63,517,961 |
9,082,948 |
|||||||||||||||||||||||
|
Advances to suppliers (including amounts of the consolidated VIEs of RMB929,167 and RMB679,196 (US$97,124) as of December 31, 2024 and 2025, respectively) |
929,167 |
679,196 |
97,124 |
|||||||||||||||||||||||
|
Total current assets |
37,497,413 |
104,966,626 |
15,010,029 |
|||||||||||||||||||||||
|
Property and equipment, net (including amounts of the consolidated VIEs of RMB461,362 and RMB1,246,568 (US$178,257) as of December 31, 2024 and 2025, respectively) |
461,362 |
1,246,568 |
178,257 |
|||||||||||||||||||||||
|
Other non-current assets (including amounts of the consolidated VIEs of RMB831,132 and RMB1,344,232 (US$192,223) as of December 31, 2024 and 2025, respectively) |
831,132 |
1,344,232 |
192,223 |
|||||||||||||||||||||||
|
Deferred offering costs (including amounts of the consolidated VIEs of RMB7,437,679 and nil as of December 31, 2024 and 2025, respectively) |
7,437,679 |
— |
— |
|||||||||||||||||||||||
|
Total non-current assets |
8,730,173 |
2,590,800 |
370,480 |
|||||||||||||||||||||||
|
Total assets |
46,227,586 |
107,557,426 |
15,380,509 |
|||||||||||||||||||||||
|
Liabilities |
||||||||||||||||||||||||||
|
Current liabilities: |
||||||||||||||||||||||||||
|
Accounts payable (including amounts of the consolidated VIEs of RMB25,320,486 and RMB44,813,902 (US$6,408,303) as of December 31, 2024 and 2025, respectively) |
25,320,486 |
44,813,902 |
6,408,303 |
|||||||||||||||||||||||
|
Accounts payable – a related party (including amounts of the consolidated VIEs of RMB25,891 and RMB7,296 (US$1,043) as of December 31, 2024 and 2025, respectively) |
25,891 |
7,296 |
1,043 |
|||||||||||||||||||||||
|
Short-term bank loans (including amounts of the consolidated VIEs of RMB34,958,333 and RMB53,000,000 (US$7,578,899) as of December 31, 2024 and 2025, respectively) |
34,958,333 |
53,000,000 |
7,578,899 |
|||||||||||||||||||||||
|
Long-term bank loans, current (including amounts of the consolidated VIEs of RMB300,000 and RMB3,700,000 (US$529,093) as of December 31, 2024 and 2025, respectively) |
300,000 |
3,700,000 |
529,093 |
|||||||||||||||||||||||
|
Long-term loans, current (including amounts of the consolidated VIEs of RMB10,000,000 and RMB10,000,000 (US$1,429,981) as of December 31, 2024 and 2025, respectively) |
10,000,000 |
10,000,000 |
1,429,981 |
|||||||||||||||||||||||
|
Long-term loans from third parties, current (including amounts of the consolidated VIEs of RMB2,320,082 and RMB200,000 (US$28,600) as of December 31, 2024 and 2025, respectively) |
2,320,082 |
200,000 |
28,600 |
|||||||||||||||||||||||
|
Salary and welfare payable (including amounts of the consolidated VIEs of RMB15,375,537 and RMB14,477,975 (US$2,070,323) as of December 31, 2024 and 2025, respectively) |
15,375,537 |
14,477,975 |
2,070,323 |
|||||||||||||||||||||||
|
Advance from customers (including amounts of the consolidated VIEs of RMB1,756,046 and RMB1,591,131 (US$227,529) as of December 31, 2024 and 2025, respectively) |
1,756,046 |
1,591,131 |
227,529 |
|||||||||||||||||||||||
|
Value added tax (“VAT”) and other tax payable (including amounts of the consolidated VIEs of RMB815,462 and RMB658,492 (US$94,163) as of December 31, 2024 and 2025, respectively) |
815,462 |
658,983 |
94,233 |
|||||||||||||||||||||||
|
Other payables (including amounts of the consolidated VIEs of RMB12,888,550 and RMB11,817,179 (US$1,689,838) as of December 31, 2024 and 2025, respectively) |
12,888,750 |
11,817,379 |
1,689,865 |
|||||||||||||||||||||||
|
Accrued liabilities (including amounts of the consolidated VIEs of RMB9,712,966 and RMB14,231,003 (US$2,035,006) as of December 31, 2024 and 2025, respectively) |
9,712,966 |
14,580,658 |
2,085,008 |
|||||||||||||||||||||||
|
Short-term loans from third parties (including amounts of the consolidated VIEs of RMB11,551,614 and RMB610,637 (US$87,320) as of December 31, 2024 and 2025, respectively) |
11,551,614 |
610,637 |
87,320 |
|||||||||||||||||||||||
|
Loans from related parties, current (including amounts of the consolidated VIEs of RMB13,821,875 and RMB15,198,309 (US$2,173,329) as of December 31, 2024 and 2025, respectively) |
13,821,875 |
15,198,309 |
2,173,329 |
|||||||||||||||||||||||
|
Amount due to related parties (including amounts of the consolidated VIEs of RMB36,829,010 and RMB92,331,116 (US$13,203,174) as of December 31, 2024 and 2025, respectively) |
36,829,010 |
45,966,864 |
6,573,174 |
|||||||||||||||||||||||
|
Operating lease liabilities, current (including amounts of the consolidated VIEs of RMB1,388,863 and RMB1,545,002 (US$220,932) as of December 31, 2024 and 2025, respectively) |
1,388,863 |
1,545,002 |
220,932 |
|||||||||||||||||||||||
|
Other current liabilities (including amounts of the consolidated VIEs of RMB2,080,556 and nil as of December 31, 2024 and 2025, respectively) |
2,080,556 |
— |
— |
|||||||||||||||||||||||
|
Total current liabilities |
179,145,471 |
218,168,136 |
31,197,632 |
|||||||||||||||||||||||
|
Long-term bank loans, noncurrent (including amounts of the consolidated VIEs of RMB8,400,000 and RMB11,000,000 (US$1,572,979) as of December 31, 2024 and 2025, respectively) |
8,400,000 |
11,000,000 |
1,572,979 |
|||||||||||||||||||||||
|
Long-term loans from third parties, noncurrent (including amounts of the consolidated VIEs of nil and RMB2,000,582 (US$286,079) as of December 31, 2024 and 2025, respectively) |
— |
2,000,582 |
286,079 |
|||||||||||||||||||||||
|
Loans from related parties, noncurrent (including amounts of the consolidated VIEs of RMB356,690,859 and RMB356,390,859 (US$50,963,215) as of December 31, 2024 and 2025, respectively) |
356,690,859 |
356,390,859 |
50,963,215 |
|||||||||||||||||||||||
|
Operating lease liabilities, noncurrent (including amounts of the consolidated VIEs of RMB1,672,218 and RMB1,294,510 (US$185,112) as of December 31, 2024 and 2025, respectively) |
1,672,218 |
1,294,510 |
185,112 |
|||||||||||||||||||||||
|
Total non-current liabilities |
366,763,077 |
370,685,951 |
53,007,385 |
|||||||||||||||||||||||
|
Total liabilities |
545,908,548 |
588,854,087 |
84,205,017 |
|||||||||||||||||||||||
|
Commitments and contingencies |
— |
— |
— |
|||||||||||||||||||||||
|
Mezzanine equity |
||||||||||||||||||||||||||
|
Convertible redeemable preferred shares (US$0.0001 par value; 12,597,228 shares authorized, 12,597,228 shares and nil issued and outstanding as of December 31, 2024 and 2025, respectively) |
1,595,051,558 |
— |
— |
|||||||||||||||||||||||
|
Redeemable non-controlling interests |
168,671,234 |
— |
— |
|||||||||||||||||||||||
|
Total mezzanine equity |
1,763,722,792 |
— |
— |
|||||||||||||||||||||||
|
Deficit |
||||||||||||||||||||||||||
|
Class A Ordinary shares (US$0.0001 par value; 450,000,000 shares authorized, 4,268,156 and 21,140,922 shares issued and outstanding as of December 31, 2024 and 2025, respectively) |
2,988 |
14,997 |
2,145 |
|||||||||||||||||||||||
|
Class B Ordinary shares (US$0.0001 par value; 2,042,042 shares authorized and outstanding as of December 31, 2024 and 2025, respectively) |
1,408 |
1,408 |
201 |
|||||||||||||||||||||||
|
Subscription receivable |
(1,608 |
) |
(2,186 |
) |
(313 |
) |
||||||||||||||||||||
|
Additional paid-in capital |
— |
2,023,765,569 |
289,394,627 |
|||||||||||||||||||||||
|
Accumulated deficit |
(2,263,419,477 |
) |
(2,475,998,594 |
) |
(354,063,090 |
) |
||||||||||||||||||||
|
Accumulated other comprehensive (loss) |
(5,231 |
) |
(1,752,460 |
) |
(250,598 |
) |
||||||||||||||||||||
|
Total Pomdoctor Limited’s shareholders’ deficit |
(2,263,421,920 |
) |
(453,971,266 |
) |
(64,917,028 |
) |
||||||||||||||||||||
|
Noncontrolling interests |
18,166 |
(27,325,395 |
) |
(3,907,480 |
) |
|||||||||||||||||||||
|
Total deficit |
(2,263,403,754 |
) |
(481,296,661 |
) |
(68,824,508 |
) |
||||||||||||||||||||
|
Total liabilities, mezzanine equity and deficit |
46,227,586 |
107,557,426 |
15,380,509 |
|||||||||||||||||||||||
|
* |
Ordinary shares and share data have been retroactively restated to give effect to the nominal share issuance for the Reorganization completed on August 8, 2024. |
POMDOCTOR LIMITED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
|
For the Years Ended December 31, |
||||||||||||||||
|
2023 |
2024 |
2025 |
2025 |
|||||||||||||
|
RMB |
RMB |
RMB |
US$ |
|||||||||||||
|
Net revenues – third parties |
304,729,898 |
341,328,781 |
399,359,702 |
57,107,678 |
||||||||||||
|
Net revenues – a related party |
123,073 |
1,229,139 |
555,262 |
79,401 |
||||||||||||
|
Net revenues |
304,852,971 |
342,557,920 |
399,914,964 |
57,187,079 |
||||||||||||
|
Cost of revenues |
266,131,202 |
294,863,867 |
347,632,853 |
49,710,837 |
||||||||||||
|
Gross profit |
38,721,769 |
47,694,053 |
52,282,111 |
7,476,242 |
||||||||||||
|
Operating expenses: |
||||||||||||||||
|
Sales and marketing expenses (including related party amounts of nil, nil and RMB1,172,706 (US$167,695) for the years ended December 31, 2023, 2024 and 2025, respectively) |
43,678,681 |
56,366,433 |
96,214,406 |
13,758,477 |
||||||||||||
|
General and administrative expenses |
12,314,018 |
11,878,335 |
59,729,352 |
8,541,184 |
||||||||||||
|
Research and development expenses |
3,370,945 |
3,002,040 |
12,864,656 |
1,839,621 |
||||||||||||
|
Impairment loss on long-lived assets |
1,107,027 |
2,238,525 |
2,108,517 |
301,514 |
||||||||||||
|
Impairment loss on long-term investment |
500,000 |
— |
— |
— |
||||||||||||
|
Total operating expenses |
60,970,671 |
73,485,333 |
170,916,931 |
24,440,796 |
||||||||||||
|
Loss from operations |
(22,248,902 |
) |
(25,791,280 |
) |
(118,634,820 |
) |
(16,964,554 |
) |
||||||||
|
Other expense, net: |
||||||||||||||||
|
Other income |
163,622 |
1,238,538 |
496,122 |
70,945 |
||||||||||||
|
Other expense |
(1,336,595 |
) |
(37,608 |
) |
(60,325 |
) |
(8,625 |
) |
||||||||
|
Interest expense (including related party amounts of RMB9,900,417, RMB8,621,249 and RMB8,118,160 (US$1,160,881) for the year ended December 31, 2023, 2024 and 2025, respectively) |
(13,849,119 |
) |
(12,964,584 |
) |
(12,885,122 |
) |
(1,842,548 |
) |
||||||||
|
Government grants |
321,573 |
189,500 |
152,599 |
21,821 |
||||||||||||
|
Total other expense, net |
(14,700,519 |
) |
(11,574,154 |
) |
(12,296,726 |
) |
(1,758,407 |
) |
||||||||
|
Loss before income tax |
(36,949,421 |
) |
(37,365,434 |
) |
(130,931,546 |
) |
(18,722,961 |
) |
||||||||
|
Income tax expense |
— |
— |
(375 |
) |
(54 |
) |
||||||||||
|
Net loss |
(36,949,421 |
) |
(37,365,434 |
) |
(130,931,921 |
) |
(18,723,015 |
) |
||||||||
|
Accretion to redemption value of mezzanine equity |
(108,440,354 |
) |
(105,969,614 |
) |
(81,648,716 |
) |
(11,675,611 |
) |
||||||||
|
Less: Net income (loss) attributable to noncontrolling interests |
1,057 |
25,878 |
(1,520 |
) |
(217 |
) |
||||||||||
|
Net loss attributable to the Pomdoctor Limited’s ordinary shareholders |
(145,390,832 |
) |
(143,360,926 |
) |
(212,579,117 |
) |
(30,398,409 |
) |
||||||||
|
Net loss |
(36,949,421 |
) |
(37,365,434 |
) |
(130,931,921 |
) |
(18,723,015 |
) |
||||||||
|
Other comprehensive loss: |
||||||||||||||||
|
Foreign currency translation adjustments, net of nil income taxes |
— |
(5,231 |
) |
(1,747,229 |
) |
(249,850 |
) |
|||||||||
|
Total comprehensive loss |
(36,949,421 |
) |
(37,370,665 |
) |
(132,679,150 |
) |
(18,972,865 |
) |
||||||||
|
Accretion to redemption value of mezzanine equity |
(108,440,354 |
) |
(105,969,614 |
) |
(81,648,716 |
) |
(11,675,611 |
) |
||||||||
|
Less: comprehensive income (loss) attributable to noncontrolling interests |
1,057 |
25,878 |
(1,520 |
) |
(217 |
) |
||||||||||
|
Comprehensive loss attributable to the Pomdoctor Limited’s ordinary shareholders |
(145,390,832 |
) |
(143,366,157 |
) |
(214,326,346 |
) |
(30,648,259 |
) |
||||||||
|
Loss per share |
||||||||||||||||
|
Basic and diluted |
(23.04 |
) |
(22.72 |
) |
(21.96 |
) |
(3.14 |
) |
||||||||
|
Weighted average number of ordinary shares outstanding* |
||||||||||||||||
|
Basic and diluted |
6,310,198 |
6,310,198 |
9,680,622 |
9,680,622 |
||||||||||||
|
* |
Ordinary shares and share data have been retroactively restated to give effect to the nominal share issuance for the Reorganization completed on August 8, 2024. |
POMDOCTOR LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
For the Years Ended December 31, |
|||||||||||||||||||||||||||||
|
2023 |
2024 |
2025 |
2025 |
||||||||||||||||||||||||||
|
RMB |
RMB |
RMB |
US$ |
||||||||||||||||||||||||||
|
Cash flows from operating activities: |
|||||||||||||||||||||||||||||
|
Net loss |
(36,949,421 |
) |
(37,365,434 |
) |
(130,931,921 |
) |
(18,723,015 |
) |
|||||||||||||||||||||
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|||||||||||||||||||||||||||||
|
Depreciation of property and equipment |
112,092 |
134,510 |
149,307 |
21,351 |
|||||||||||||||||||||||||
|
Change in expected credit losses |
1,488,459 |
841,683 |
(240,982 |
) |
(34,460 |
) |
|||||||||||||||||||||||
|
Allowance for inventory |
503,079 |
494,459 |
1,883,635 |
269,355 |
|||||||||||||||||||||||||
|
Share base payment |
— |
— |
16,423,683 |
2,348,555 |
|||||||||||||||||||||||||
|
Impairment loss on long-lived assets |
1,107,027 |
2,238,525 |
2,108,517 |
301,514 |
|||||||||||||||||||||||||
|
Impairment loss on long-term investment |
500,000 |
— |
— |
— |
|||||||||||||||||||||||||
|
Gain/(Loss) on disposal of property and equipment |
— |
(3,893 |
) |
— |
— |
||||||||||||||||||||||||
|
Changes in operating assets and liabilities: |
|||||||||||||||||||||||||||||
|
Accounts receivable |
(1,273,526 |
) |
20,309,367 |
(10,099,387 |
) |
(1,444,193 |
) |
||||||||||||||||||||||
|
Accounts receivable – a related party |
— |
(424,259 |
) |
(407,177 |
) |
(58,226 |
) |
||||||||||||||||||||||
|
Amount due from related parties |
831,665 |
(3,229,309 |
) |
1,995,948 |
285,417 |
||||||||||||||||||||||||
|
Inventories |
(5,001,966 |
) |
3,033,987 |
(997,807 |
) |
(142,684 |
) |
||||||||||||||||||||||
|
Other receivables |
(4,011,854 |
) |
(210,043 |
) |
(57,924,742 |
) |
(8,283,128 |
) |
|||||||||||||||||||||
|
Advances to suppliers |
(53,696 |
) |
1,950,808 |
249,971 |
35,745 |
||||||||||||||||||||||||
|
Other non-current assets |
(171,874 |
) |
(281,632 |
) |
86,900 |
12,427 |
|||||||||||||||||||||||
|
Accounts payable |
(1,627,218 |
) |
(16,254,687 |
) |
19,493,416 |
2,787,521 |
|||||||||||||||||||||||
|
Accounts payable – a related party |
(30,908 |
) |
(88,034 |
) |
(18,595 |
) |
(2,659 |
) |
|||||||||||||||||||||
|
Salary and welfare payable |
(3,400,663 |
) |
149,452 |
(897,562 |
) |
(128,350 |
) |
||||||||||||||||||||||
|
Advance from customers |
(1,489,222 |
) |
512,618 |
(164,915 |
) |
(23,583 |
) |
||||||||||||||||||||||
|
Value added tax (“VAT”) and other tax payable |
(115,371 |
) |
601,150 |
(156,479 |
) |
(22,376 |
) |
||||||||||||||||||||||
|
Other payables |
(3,001,148 |
) |
3,391,790 |
1,300,394 |
185,954 |
||||||||||||||||||||||||
|
Accrued liabilities |
(96,449 |
) |
(82,393 |
) |
4,867,692 |
696,071 |
|||||||||||||||||||||||
|
Amount due to related parties |
8,879,617 |
7,145,948 |
9,137,854 |
1,306,696 |
|||||||||||||||||||||||||
|
Operating lease liabilities |
(1,994,305 |
) |
(1,076,049 |
) |
(2,256,846 |
) |
(322,725 |
) |
|||||||||||||||||||||
|
Refund liability |
— |
2,080,556 |
(2,080,556 |
) |
(297,516 |
) |
|||||||||||||||||||||||
|
Net cash used in operating activities |
(45,795,682 |
) |
(16,130,880 |
) |
(148,479,652 |
) |
(21,232,309 |
) |
|||||||||||||||||||||
|
Cash flows from investing activities: |
|||||||||||||||||||||||||||||
|
Payment for purchase of property and equipment |
(111,891 |
) |
(37,773 |
) |
(1,007,753 |
) |
(144,107 |
) |
|||||||||||||||||||||
|
Payment for other noncurrent assets |
— |
— |
(600,000 |
) |
(85,799 |
) |
|||||||||||||||||||||||
|
Proceeds from disposal of property and equipment |
— |
4,400 |
— |
— |
|||||||||||||||||||||||||
|
Net cash used in investing activities |
(111,891 |
) |
(33,373 |
) |
(1,607,753 |
) |
(229,906 |
) |
|||||||||||||||||||||
|
Cash flows from financing activities: |
|||||||||||||||||||||||||||||
|
Loans from related parties |
104,430,113 |
15,301,351 |
24,778,594 |
3,543,292 |
|||||||||||||||||||||||||
|
Repayment to related parties |
(64,460,091 |
) |
(25,047,012 |
) |
(23,702,159 |
) |
(3,389,364 |
) |
|||||||||||||||||||||
|
Proceeds from short-term bank loans |
28,000,000 |
44,100,000 |
56,000,000 |
8,007,893 |
|||||||||||||||||||||||||
|
Repayment of short-term bank loans |
(15,664,494 |
) |
(31,141,667 |
) |
(37,958,333 |
) |
(5,427,969 |
) |
|||||||||||||||||||||
|
Proceeds from long-term bank loans |
3,000,000 |
6,000,000 |
7,000,000 |
1,000,987 |
|||||||||||||||||||||||||
|
Repayment of long-term bank loans |
— |
(847,295 |
) |
(1,000,000 |
) |
(142,998 |
) |
||||||||||||||||||||||
|
Repayment of long-term loans |
(470,272 |
) |
(391,667 |
) |
(119,500 |
) |
(17,088 |
) |
|||||||||||||||||||||
|
Loans from third parties |
1,124,048 |
19,856,630 |
2,951,275 |
422,027 |
|||||||||||||||||||||||||
|
Repayment to third parties |
(3,615,200 |
) |
(10,814,260 |
) |
(13,892,252 |
) |
(1,986,566 |
) |
|||||||||||||||||||||
|
Proceeds from IPO |
— |
— |
163,932,614 |
23,442,052 |
|||||||||||||||||||||||||
|
Payment for deferred offering cost |
(2,276,926 |
) |
— |
(24,063,528 |
) |
(3,441,039 |
) |
||||||||||||||||||||||
|
Net cash provided by financing activities |
50,067,178 |
17,016,080 |
153,926,711 |
22,011,227 |
|||||||||||||||||||||||||
|
Effect of exchange rate changes |
— |
(5,231 |
) |
(1,910,634 |
) |
(273,217 |
) |
||||||||||||||||||||||
|
Net increase in cash and cash equivalents and restricted cash |
4,159,605 |
846,596 |
1,928,672 |
275,796 |
|||||||||||||||||||||||||
|
Cash and cash equivalents and restricted cash at beginning of the year |
2,645,494 |
6,805,099 |
7,651,695 |
1,094,178 |
|||||||||||||||||||||||||
|
Cash and cash equivalents and restricted cash at end of the year |
6,805,099 |
7,651,695 |
9,580,367 |
1,369,974 |
|||||||||||||||||||||||||
|
Including: |
|||||||||||||||||||||||||||||
|
Cash and cash equivalents at beginning of the year |
2,485,598 |
6,717,031 |
7,651,695 |
1,094,178 |
|||||||||||||||||||||||||
|
Restricted cash at beginning of the year |
159,896 |
88,068 |
— |
— |
|||||||||||||||||||||||||
|
Cash and cash equivalents and restricted cash at end of the year |
6,805,099 |
7,651,695 |
9,580,367 |
1,369,974 |
|||||||||||||||||||||||||
|
Including: |
|||||||||||||||||||||||||||||
|
Cash and cash equivalents at end of the year |
6,717,031 |
7,651,695 |
9,580,367 |
1,369,974 |
|||||||||||||||||||||||||
|
Restricted cash at end of the year |
88,068 |
— |
— |
— |
|||||||||||||||||||||||||
|
Supplemental disclosures of cash flows information: |
|||||||||||||||||||||||||||||
|
Cash paid for income tax |
— |
— |
— |
— |
|||||||||||||||||||||||||
|
Cash paid for interest expense |
2,388,025 |
2,744,793 |
2,703,601 |
386,610 |
|||||||||||||||||||||||||
|
Supplemental disclosure of noncash investing and financing activities: |
|||||||||||||||||||||||||||||
|
Property and equipment acquired by assuming a long-term loan |
640,000 |
— |
— |
— |
|||||||||||||||||||||||||
|
Operating lease right-of-use assets obtained in exchange for new operating lease liabilities |
1,063,104 |
2,200,752 |
2,035,277 |
291,041 |
|||||||||||||||||||||||||
|
Conversion of convertible redeemable preferred shares into Class A ordinary shares upon IPO |
— |
— |
1,668,974,247 |
238,660,143 |
|||||||||||||||||||||||||
|
Conversion of convertible redeemable non-controlling interest into non-controlling interest upon IPO |
— |
— |
176,397,261 |
25,224,473 |
|||||||||||||||||||||||||
|
Reclassification of deferred offering costs to additional paid-in capital |
— |
— |
29,129,441 |
4,165,455 |
|||||||||||||||||||||||||
|
Expensed of deferred offering costs before IPO |
— |
— |
1,624,680 |
232,326 |
|||||||||||||||||||||||||
|
Net off deferred offering costs to other payable |
— |
— |
747,087 |
106,832 |
|||||||||||||||||||||||||
ข่าวที่เกี่ยวข้อง
- High‑Trend International Group Announces Cancellation and Retirement of 630,000 Class A Ordinary Shares
- CGTN: ‘เสถียรภาพเชิงยุทธศาสตร์อย่างสร้างสรรค์’: จีนและสหรัฐฯ ร่วมกำหนดวิสัยทัศน์ใหม่ให้แก่ความสัมพันธ์ทั้งสองประเทศ
- Artmarket.com: แถลงการณ์ Artprice: 22 กฎสำหรับตลาดศิลปะที่มีการควบคุมและโปร่งใสในยุคแห่ง AI
- DeepQure Reports Encouraging Clinical Data from World’s First Extravascular RDN System at AUA 2026
